For adults struggling with primary nephrotic syndrome, losing too much protein in urine can be exhausting and scary. A recent analysis looked at how adding Bailing Capsule to standard care changes the picture. The review combined data from 920 patients to see if this treatment made a real difference.
The results were promising. Patients taking Bailing Capsule alongside their usual therapy saw significant drops in protein loss, creatinine, and blood urea nitrogen. Their cholesterol levels went down, while their blood albumin levels rose markedly. The treatment also boosted immune cell counts and improved the overall clinical response rate for these patients.
Safety was another key concern. The study found that adverse events were rare, and the drug had a favorable safety profile. However, experts note that conclusions from current studies are sometimes inconsistent. They emphasize that further large-scale trials are needed to fully validate long-term effectiveness and safety before this becomes a standard option.
